Advertisement

Pharmacy World & Science

, 31:689 | Cite as

Improvement of diabetes indices of care by a short pharmaceutical care program

  • Mertkan Turnacilar
  • Mesut Sancar
  • Sule Apikoglu-Rabus
  • Mehmet Hursitoglu
  • Fikret Vehbi IzzettinEmail author
Research Article

Abstract

Objective Diabetes mellitus is a serious health problem associated with an increased mortality and morbidity. The association of improved glycemic control with sustained decrease in the rate of complications has been shown in randomized clinical trials. Pharmaceutical care is a relatively new concept in Turkey; yet, there are no recorded routine pharmaceutical care programs. Therefore, we aimed to assess the impact of a short pharmaceutical care program conducted in the community pharmacy setting, on the indices of diabetes care of type 2 diabetic patients, particularly those regarding glycemic control and high blood pressure management. Setting The study was carried out at eight community pharmacies in Pendik district of Istanbul. Method All patients who visited any of the eight pharmacies through the pre-determined 1-week period were questioned for the presence of type 2 diabetes. Patients who reported to be type 2 diabetic (n = 67) were informed about the study and invited to involve. During this prospective longitudinal study, pharmaceutical care was provided to the patients by the same clinical pharmacist. The 3 month pharmaceutical care period consisted of six pharmacy visits. Main outcome measure: The main outcome measures were the improvement in glycemic control and blood pressure control; while, weight control, self-monitoring of blood glucose, compliance and being under physician-control were also assessed. Results The study was conducted on 43 patients who accepted to involve. Fasting blood glucose was lowered by a mean of 23% over 3-months from an initial value of 167.2 mg/dl. Number of patients reaching the desired blood glucose goals increased from 16.3% to 39.5%. Systolic and diastolic blood pressures also significantly fell over 3 months (mean reductions were 10.9 mmHg for the systolic and 9.3 mmHg for the diastolic blood pressure). Number of patients reaching the desired blood pressure goal increased from 30.2% to 51.2%. Conclusion Our short-course pharmaceutical care program yielded measurable improvements in clinical indicators of diabetes and comorbidity management. The results suggest that the pharmacist is a beneficial key component of integrated care for patients with type 2 diabetes. We think that the positive results observed in this first reported pharmaceutical care program on diabetes in Turkey can be motivating and encouraging for all community pharmacists.

Keywords

Diabetes Pharmaceutical care Glycemic control Blood pressure Clinical pharmacist Turkey 

Notes

Acknowledgement

This study was approved by Marmara University, Faculty of Medicine, Local Ethics Committee. Glucometer, BG electrode, glucometer-electrode calibration apparatus and control solutions were kindly provided by MediSense Optium- Abbott Pharmaceutical Inc. (Istanbul, Turkey).

Funding

The authors funded the study themselves; no external funding was applicable.

Conflict of interest

The authors have no conflicts of interest.

References

  1. 1.
    Matzer S, Leiter L, Daneman D, Gerstein H, Lau D, Ludwig S, et al. Clinical practice guidelines for the management of diabetes in Canada. CMAJ. 1998;159:1–29.Google Scholar
  2. 2.
    American Diabetes Association: Implications of the diabetes control and complications trial. Diabetes Care 2002; 25: 25–7.Google Scholar
  3. 3.
    Abuissa H, Bel DS, O’Keefe JH Jr. Strategies to prevent type 2 diabetes. Curr Med Res Opin. 2005;21:1107–14.CrossRefPubMedGoogle Scholar
  4. 4.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.CrossRefPubMedGoogle Scholar
  5. 5.
    The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977–86.Google Scholar
  6. 6.
    The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342: 381–9.Google Scholar
  7. 7.
    UK Prospective Diabetes Study (UKPDS) Group: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837–53.Google Scholar
  8. 8.
    UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.Google Scholar
  9. 9.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703–13.Google Scholar
  10. 10.
    Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. HOT Study Group: effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Garção JA, Cabrita J. Evaluation of a pharmaceutical care program for hypertensive patients in rural Portugal. J Am Pharm Assoc. 2002;42:858–64.CrossRefGoogle Scholar
  13. 13.
    Gonzalez-Martin G, Joo I, Sanchez I. Evaluation of the impact of a pharmaceutical care program in children with asthma. Patient Educ Couns. 2003;49:13–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Paulos CP, Nygren CE, Celedon C, Carcama CA. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Ann Pharmacother. 2005;39:939–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Clark PM, Karagoz T, Apikoglu-Rabus S, Izzettin FV. Effect of pharmacist-led patient education on adherence to tuberculosis treatment. Am J Health-Syst Pharm. 2007;64:497–506.CrossRefPubMedGoogle Scholar
  16. 16.
    Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patient with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Jaber LA, Halapi H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30:238–43.PubMedGoogle Scholar
  18. 18.
    Berringer R, Shibley MC, Cary CC, Pugh CB, Powers PA, Rafi JA. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc. 1999;39:791–7.Google Scholar
  19. 19.
    Van Veldhuizen-Scott MK, Widmer LB, Stacy SA, Popovich NG. Developing and implementing a pharmaceutical care model in an ambulatory care setting for patients with diabetes. Diabetes Educ. 1995;21:117–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team-a pilot study. Pharm World Sci. 2004;26:18–25.CrossRefPubMedGoogle Scholar
  21. 21.
    Anaya JP, Rivera JO, Lawson K, Garcia J, Luna J Jr, Ortiz M. Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm. 2008;65:1841–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Morello CM, Zadvorny EB, Cording MA, Suemoto RT, Skog J, Harari A. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health Syst Pharm. 2006;63:1325–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Irons BK, Seifert CF, Horton NA. Quality of care of a pharmacist-managed diabetes service compared to usual care in an indigent clinic. Diabetes Technol Ther. 2008;10:220–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Fera T, Bluml BM, Ellis WM, Schaller CW, Garrett DG. The diabetes ten city challenge: interim clinical and humanistic outcomes of a multi-site community pharmacy diabetes care program. J Am Pharm Assoc. 2008;48:181–90.CrossRefGoogle Scholar
  25. 25.
    Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:149–59.CrossRefGoogle Scholar
  26. 26.
    Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173–84.CrossRefGoogle Scholar
  27. 27.
    Cioffi ST, Caron MF, Kalus JS, Hill P, Buckley TE. Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother. 2004;38:771–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11:253–60.PubMedGoogle Scholar
  29. 29.
    Suppapitiporn S, Chindavijak B, Onsanit S. Effect of diabetes drug counselling by pharmacist, diabetic disease booklet and special medication containers on glycemic control of type 2 diabetes mellitus: a randomized controlled trial. J Med Assoc Thai. 2005;88:S134–41.PubMedGoogle Scholar
  30. 30.
    Brooks AD, Rihani RS, Derus CL. Pharmacist membership in a medical group’s diabetes health management program. Am J Health Syst Pharm. 2007;64:617–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–43.PubMedGoogle Scholar
  32. 32.
    Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician’s guide 2nd Edition The McGraw-Hill Companies, Inc. 2004 USA.Google Scholar
  33. 33.
    Al-Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2009;67:547–57.CrossRefPubMedGoogle Scholar
  34. 34.
    Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c, analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275–8.CrossRefPubMedGoogle Scholar
  35. 35.
    McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, et al. SCRIP-HTN Investigators: A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. 2008;24(168):2355–61.CrossRefGoogle Scholar
  36. 36.
    Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm. 2006;63:2116–22.CrossRefPubMedGoogle Scholar
  37. 37.
    Vivian EM. Improving blood pressure control in a pharmacists-managed hypertension clinic. Pharmacotherapy. 2002;22:1533–40.CrossRefPubMedGoogle Scholar
  38. 38.
    Ahrens RA, Hower M, Best AM. Effects of weight reduction interventions by community pharmacists. J Am Pharm Assoc. 2003;43:583–90.CrossRefGoogle Scholar
  39. 39.
    Zillich AJ, Ryan M, Adams A, Yeager B, Farris K. Effectiveness of a pharmacist-based smoking-cessation program and its impact on quality of life. Pharmacotherapy. 2003;22:759–65.CrossRefGoogle Scholar
  40. 40.
    Clifford RM, Davis WA, Batty KT, Davis TME. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. The Fremantle Diabetes Study. Diabetes Care. 2005;28:771–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Mertkan Turnacilar
    • 1
  • Mesut Sancar
    • 1
  • Sule Apikoglu-Rabus
    • 1
  • Mehmet Hursitoglu
    • 2
  • Fikret Vehbi Izzettin
    • 1
    Email author
  1. 1.Clinical Pharmacy Department, Faculty of PharmacyMarmara UniversityIstanbulTurkey
  2. 2.Internal Medicine DepartmentVakif Gureba Teaching and Research HospitalIstanbulTurkey

Personalised recommendations